<DOC>
	<DOCNO>NCT00415454</DOCNO>
	<brief_summary>The primary purpose phase I study determine safety combine replication-competent adenovirus-mediated suicide gene therapy chemoradiotherapy patient non-metastatic pancreatic cancer .</brief_summary>
	<brief_title>Study Combining Suicide Gene Therapy With Chemoradiotherapy Treatment Non-Metastatic Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>The objective study : To determine toxicity maximum tolerate dose ( MTD ) Ad5-yCD/mutTKSR39rep-ADP adenovirus combination 5-fluorocytosine ( 5-FC ) valganciclovir ( vGCV ) prodrug therapy standard chemoradiation . Fifteen 30 subject ( 5 cohort 3 - 6 subject ) non-metastatic , unresectable pancreatic cancer receive single intratumoral injection Ad5-yCD/mutTKSR39rep-ADP adenovirus one five dose level ( 1 x 10e10 vp , 3 x 10e10 vp , 1 x 10e11 vp , 3 x 10e11 vp , 1 x 10e12 vp ) endoscopic ultrasound ( EUS ) -guidance . Beginning three day later , subject receive 3 week ( 15 day ) 5-FC vGCV prodrug therapy concomitant 6 week ( 30 day ) course capecitabine chemotherapy 54 Gy conformal radiotherapy . The primary endpoint toxicity 12 week . Secondary endpoint : 1 ) tumor ( radiological ) response , 2 ) time disease progression , 3 ) survival , 4 ) persistence Ad5-yCD/mutTKSR39rep-ADP adenoviral DNA blood , 5 ) infectious Ad5-yCD/mutTKSR39rep-ADP adenovirus blood , 6 ) HSV-1 TK gene expression pancreas .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Suicide</mesh_term>
	<criteria>Age &gt; = 18 &lt; = 80 . Nonmetastatic , unresectable tumor No evidence peritoneal and/or hematogenous metastasis . Histologically proven ( biopsy cytology ) adenocarcinoma . No evidence peritoneal and/or hematogenous metastasis . No prior chemotherapy , radiotherapy biological therapy . ECOG performance status 0 2 . Subjects must adequate baseline organ function , assess follow laboratory value , within 30 day initiate study therapy : Adequate renal function serum creatinine &lt; =1.5 mg/dL creatinine clearance &gt; =50 mL/min/m2 . Absolute WBC &gt; 4,000/μL . Hemoglobin &gt; 9.0 g/dL . Platelet count &gt; 100,000/μL . Bilirubin &lt; 1.5 mg/dL ; SGOT SGPT &lt; 2.5 time upper limit normal ( ULN ) . No history malignancy within 5 year except nonmelanomatous skin cancer carcinoma situ cervix . Men woman conceptive potential must agree follow medically acceptable method birth control . Patients oral warfarin anticoagulation therapy may include study , must close monitoring coagulation parameter alter parameter and/or bleed report patient take Xeloda® agent concomitantly . The subject must possess ability give inform consent express willingness meet expect requirement protocol duration study . Pregnant lactate woman . Serious nonmalignant disease ( e.g. , congestive heart failure uncontrolled infection ) , , opinion investigator would compromise study objective . Major surgery within four week diagnostic procedure laparoscopy , endoscopic ultrasound stenting PEG/PEJ placement . Islet cell tumor , benign cyst , periampullary carcinoma nonadenocarcinomas . Acute infection . Acute infection define viral , bacterial , fungal infection require specific therapy within 72 hour initiation study therapy ( define Day 1 ) . Active HIV disease . Previous history liver disease include hepatitis . Positive serologic test Hepatitis B C baseline . Immunosuppressive therapy include systemic corticosteroid . Use inhale topical corticosteroid permit . Serious medical psychiatric illness concomitant medication , , judgment investigator , might interfere subject 's ability respond tolerate treatment complete trial . Impaired immunity susceptibility serious viral infection . Allergy product use protocol include ciprofloxacin . Clinical laboratory evidence pancreatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Pancreatic Cancer</keyword>
</DOC>